Opportunities arise for once-spurned partners
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Is biopharma getting better at accelerated approval conversions?
Amid ongoing pressure to reform the FDA’s fast-track pathway, signs emerge that the criticism is being heard.
JP Morgan 2022 – Sarepta gets another bite at the gene therapy cherry
But unimpressive phase 2 results, plus a lack of a placebo control arm, raise questions.
Pfizer adds to gene therapy woes
But another safety scare for the big pharma’s Duchenne muscular dystrophy project could be good news for Sarepta.
Astellas’s gene therapy aspirations crumble
AT132 has prompted more safety concerns, this time at a lower dose than before.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
